GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (LSE:LEL) » Definitions » Accumulated other comprehensive income (loss)

Eli Lilly and Co (LSE:LEL) Accumulated other comprehensive income (loss) : $-4,300 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Eli Lilly and Co's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was $-4,300 Mil.

Eli Lilly and Co's quarterly Accumulated other comprehensive income (loss) declined from Sep. 2023 ($-3,785 Mil) to Dec. 2023 ($-4,327 Mil) but then increased from Dec. 2023 ($-4,327 Mil) to Mar. 2024 ($-4,300 Mil).

Eli Lilly and Co's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 ($-4,343 Mil) to Dec. 2022 ($-3,845 Mil) but then declined from Dec. 2022 ($-3,845 Mil) to Dec. 2023 ($-4,327 Mil).

Eli Lilly and Co Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Eli Lilly and Co's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Accumulated other comprehensive income (loss) Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,523.60 -6,496.40 -4,343.10 -3,844.60 -4,327.00

Eli Lilly and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,777.30 -3,788.70 -3,784.90 -4,327.00 -4,299.50

Eli Lilly and Co Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Eli Lilly and Co Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co (LSE:LEL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (LSE:LEL) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
JNJ MRK ABBV AMGN PFE BMY GILD BIIB OGN AMRN LSE:AZN XSWX:NOVN XSWX:ROG XPAR:SAN LSE:GSK TSE:4568 TSE:4519 SHSE:600276 XTER:BAYN TSE:4578
Traded in Other Exchanges
LLY:USA LLY:Mexico 1LLY:Italy LLY:Germany LLY:Switzerland LLY:Canada LILY34:Brazil LLYC:Austria LLY:Argentina
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Website
https://www.lilly.com
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (LSE:LEL) Headlines

No Headlines